

## Cyclodextrin microparticles for ocular drug delivery targeted to the posterior segment of the eye

The conventional ophthalmic drug delivery systems cannot ensure the required concentration of the drug due to the short contact time of the formulations on the epithelium and fast elimination of drugs. To overcome these problems various concepts such as prodrugs, solubilizers (cyclodextrins), penetration enhancers and other ocular drug delivery systems such as gels, in-situ forming gels with temperature-, pH-, or osmotically induced gelation, combination of polymers and colloidal systems such as liposomes, microemulsions, nanoemulsions, niosomes, cubosomes and nanoparticles have been studied (Achuri et al., 2013).

According to the Cyclodextrin News database containing over 300 entries on ophthalmic application of cyclodextrins, the development of cyclodextrin-containing ophthalmic formulations started in the eighties with solubilization/stabilization of steroids and non-steroidal antiinflammatory drugs. In certain studies the complexation resulted in slightly improved bioavailability and reduced irritancy. Based on the three decades of research and development there are at least 5 CD-enabled eye drop formulations on the market (Table 1).

Table 1 CD-containing eye drops marketed

<b>Drug</b>	<b>CD</b>	<b>Trade name</b>	<b>Company</b>
Chloramphenicol	RAMEB	Clorocil	Oftalder (Portugal)
Diclofenac	HPGCD	Voltaren/ Voltarol	Novartis (Schwitzerland)
Indomethacin	HPBCD	Indocid/Indocyllir	Chauvin (UK)/ Bausch & Lomb (US)
Naphasoline hydrochloride	CD	Clear eyes Cooling comfort	Medtech (S. Africa)
Thimerosal	BCD	Vitaseptol	Novartis (Schwitzerland), Europhtha (Monaco)



The recent review of Loftsson and Stefánsson (2017) gives an overview on the application of cyclodextrins in the anterior and posterior segment of the eye. From this review one can learn that drug permeation from the eye surface into the eye is usually of very low efficiency mainly because of several barriers. The first barrier is the mucus, a gel-like fluid layer consisting of water (90–98%) and glycoproteins called mucins (2–5%). Mucins form H-bonds with the surrounding water building an unstirred water layer (UWL) hardly permeable for lipophilic drugs.

The drug permeating from the surface into the eye via passive drug diffusion follows two main routes: 1) corneal route (mucus→cornea→aqueous humor→intraocular tissues) and 2) scleral route (conjunctiva→sclera→choroid→retina). (The segments of eye are illustrated in Fig. 1).

Cornea consists of hydrophilic and lipophilic epithelium layers which hamper the penetration of lipophilic and hydrophilic drugs, respectively. Conjunctiva and sclera have also barrier function depending less on the hydrophilicity but rather on the size (molecular weight) of the drug: the permeability coefficient decreases with increasing hydrodynamic radius of the drug.

The passive transport of a drug depends also on the concentration gradient (the higher the better).

Another obstacle of the topical drug administration to the eye is the short residence time: the eye drop is mixed with tear (diluted resulting in decreased concentration then fast drying).

The higher drug concentration, the longer residence time and optimal lipophilicity (the octanol/water partition coefficient,  $K_{ow}$  between 2 and 3) are favored for drug penetration into the eye.




Fig. 1 The structure of the eye

It is especially difficult to obtain therapeutic drug concentrations in the posterior segment of the eye after topical application of aqueous, low viscosity eye drops.

The eye drops recently developed by Loftsson's group contain solid drug/cyclodextrin complex microparticles with a mean diameter of 2–4  $\mu\text{m}$ , dissolved drug/cyclodextrin complex nanoparticles and dissolved drug molecules in equilibrium in an aqueous eye drop medium of low viscosity (Fig. 2).






Fig. 2 In consequence of aggregation individual host and guest molecules are in equilibrium with inclusion complexes in non-aggregated form aggregated to nanoparticles (20–300 nm) and microparticles (1–10 μm) (redrawn from Loftsson and Stefansson, 2017)

After administration of the eye drops the microparticles slowly dissolve and maintain close to saturated drug concentrations in the aqueous tear fluid for several hours. Studies in rabbits using dexamethasone as sample drug, show that the eye drops deliver significant amounts of drugs to both the posterior segment and anterior segment of the eye while the clear solutions with RAMEB deliver the drug mainly to the anterior segment (Fig. 3).




Fig. 3 Dexamethasone concentration 120 min after topical administration to rabbit in the various segments of the eye after using 1.5% Dexamethasone formulated by RAMEB solution and by GCD microsuspension (drawn from the data in Loftsson and Stefansson, 2017)



Clinical studies indicate that the eye drops can replace intravitreal injections and implants that are currently used to treat ophthalmic diseases, such as diabetic macular edema (DME), intermediate uveitis with cystoid macular edema, and decrease frequency of drug administration, both of which provide important benefits for the patients.

Based on this concept an EU supported consortium with the members of Oculis (Reykjavik), Experimentica Ltd. (US), Medical University of Vienna, Nucro-Technics (Toronto), University of Copenhagen and Zealand University Hospital (Copenhagen) started to develop a novel eye-drop formulation for the treatment of diabetic retinopathy.

Recently, Oculis closed a financing round of CHF 20 million for going to the clinical phases in the development of breakthrough non-invasive topical treatment for back-of-the-eye diseases (Oculis, 2018). The new technology using cyclodextrin-based microparticles is expected to pave way for the next generation of ophthalmic treatments.

### References

Achouri, D.; Alhanout, K.; Piccerelle, P.; Andrieu, V. (2013) Recent advances in ocular drug delivery. *Drug Development and Industrial Pharmacy*, 39, 1599-1617

Thorsteinn Loftsson and Einar Stefansson (2017) Cyclodextrins and topical drug delivery to the anterior and posterior segments of the eye. *International Journal of Pharmaceutics*, 531, 413 - 423; DOI:<https://doi.org/10.1016/j.ijpharm.2017.04.010>

Oculis (2018) <http://oculis.com/category/news/>

## Cyclodextrin News Retrospective

### *We wrote 10, 20 and 30 years ago*

10 years ago an updated list of approved and marketed pharmaceutical products containing cyclodextrins was the topic of the first issue of Vol 22. This collection was often cited in various publications. Followed by the exhaustive listing of various drug preparations, a cordial invitation was sent to the 14th International Cyclodextrin Symposium held in Kyoto, Japan (May 8-11, 2008). The international cyclodextrin community is certainly excited that after ten years the conference re-visits Japan and the 19th International Cyclodextrin Symposium will be organized in Tokyo (April 27-30, 2018).

20 years ago, the highlighted topic was „Cyclodextrins in pulmonary drug delivery systems“.

Based on 25 publications known in 1998 related to the field, a short comprehensive outline was given on relevant questions and issues as listed below:

- Where does pulmonary drug absorption occur?
- What are the barriers for pulmonary absorption?
- What is the mechanism of pulmonary drug absorption?
- What variables affect pulmonary absorption?
- Dosing problems associated with pulmonary drug delivery.

In the resumé of Professor Szejtli a very apt short answer is given, literally: „**So CDs can help!**“

To the best of our knowledge no CD-containing pulmonary product has been successfully introduced to the market yet. However the state-of-the art approach to the potential future success lies in EMA's latest collective proposal related to the pharmaceutical use of CDs.



This document reflects to the possible pulmonary application: „Cyclodextrins are absorbed poorly via mucosal membranes, but at high doses they can increase nasal and pulmonary drug permeability by direct action on mucosal membranes and facilitate also their own absorption. They can also strongly potentiate lipophilic absorption enhancers. Less than 10% HP- $\beta$ -CD or RM- $\beta$ -CD solutions, and less than 1.5%  $\beta$ -CD solutions do not induce tissue damage in rats and can keep the integrity of the nasal mucosa” (Questions and answers on cyclodextrins used as excipients in medicinal products for human use: EMA/CHMP/495747/2013, 9 October 2017). The market potential of the field is exemplified by a granted patent entitled „[Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin And Corticosteroid](#)” owned by CyDex Pharmaceuticals, Inc., USA under patent number EP1732512.

30 years ago, Professor Szejtli postulated that it is still possible to be addictive to the passion of smoking while a smart cigarette tip is capturing the harmful substances by cyclodextrin. In his editorial entitled „Safer smoking with cyclodextrins” the ability of cyclodextrins to complex nicotine and tar components is shown. The use of this property in a filtration system led to a marketed product in Japan (Disposable Cigarette Filter) depicted in Vol 2 issue 5 of Cyclodextrin News. Professor Szejtli’s sense of humor reflected at the ending note of the editorial: „This product would seem to be an excellent idea to make smoking safer. As a non smoker, however, the logic of removing both tar and nicotine escapes me. What is left? Possibly the HCN!!”

## Bibliography & Keywords of Selected Publications of the Month

Cutrone, G.; Casas-Solvas, J. M.; Vargas-Berenguel, A.

### **Cyclodextrin-modified inorganic materials for the construction of nanocarriers**

*Gold, silver, quantum dots and magnetic nanoparticles, Biocompatibility, Multivalency*

International Journal of Pharmaceutics, 2017, 531, 621 - 639;

DOI:<https://doi.org/10.1016/j.ijpharm.2017.06.080>

Lee, D. S; Hur, P.; Kim, B. K.

### **Chemical hybridization of waterborne polyurethane with $\beta$ -cyclodextrin by sol-gel reaction**

*BCD as a biodegradable multifunctional crosslinker,  $\alpha$ -amylase enzyme*

Progress in Organic Coatings, 2017, 111, 107 - 111;

DOI:<https://doi.org/10.1016/j.porgcoat.2017.04.039>

Narayanan, G.; Boy, R.; Gupta, B. S.; Tonelli, A. E.

### **Analytical techniques for characterizing cyclodextrins and their inclusion complexes with large and small molecular weight guest molecules**

*Review*

Polymer Testing, 2017, 62, 402 - 439;

DOI:<https://doi.org/10.1016/j.polymertesting.2017.07.023>



Furuishi, T.; Takahashi, S.; Ogawa, N.; Gunji, M.; Nagase, H.; Suzuki, T.; Endo, T.; Ueda, H.; Yonemochi, E.; Tomono, K.

**Enhanced dissolution and skin permeation profiles of epalrestat with  $\beta$ -cyclodextrin derivatives using a cogrinding method**

*Methyl BCD ground mixture system with urea, Potential transdermal drug delivery system, Diabetic neuropathy.*

European Journal of Pharmaceutical Sciences, 2017, 106, 79 - 86;

DOI: <https://doi.org/10.1016/j.ejps.2017.05.047>

Wankar, J.; Salzano, G.; Pancani, E.; Benkovics, G.; Malanga, M.; Manoli, F.; Gref, R.; Fenyvesi, E.; Manet, I.

**Efficient loading of ethionamide in cyclodextrin-based carriers offers enhanced solubility and inhibition of drug crystallization**

*Polymeric BCD nanoparticles, Confined microdomains inside the crosslinked nanoparticles, Double modality of complexation*

International Journal of Pharmaceutics, 2017, 531, 568 - 576;

DOI: <https://doi.org/10.1016/j.ijpharm.2017.05.041>

Popielec, A.; Loftsson, T.

**Effects of cyclodextrins on the chemical stability of drugs**

*Hydrolysis, Oxidation, Photodegradation, Isomerization, Enzyme catalyzed degradation,  $\beta$ -lactam antibiotics*

International Journal of Pharmaceutics, 2017, 531, 532 - 542;

DOI: <https://doi.org/10.1016/j.ijpharm.2017.06.009>

Thomsen, H.; Benkovics, G.; Fenyvesi, E.; Farewell, A.; Malanga, M.; Ericson, B. M.

**Delivery of cyclodextrin polymers to bacterial biofilms – An exploratory study using rhodamine labelled cyclodextrins and multiphoton microscopy**

*Staphylococcus epidermidis, Cationic BCD-polymers*

International Journal of Pharmaceutics, 2017, 531, 650 - 657;

DOI: <https://doi.org/10.1016/j.ijpharm.2017.06.011>

Stjern, L.; Voittoinen, S.; Weldemichel, R.; Thuresson, S.; Agnes, M.; Benkovics, G.; Fenyvesi, E.; Malanga, M.; Yannakopoulou, K.; Feiler, A.; Valetti, S.

**Cyclodextrin-mesoporous silica particle composites for controlled antibiotic release. A proof of concept toward colon targeting**

*CD as gatekeeper, Metronidazole, Clofazimine, Benzyl-modified silica*

International Journal of Pharmaceutics, 2017, 531, 595 - 605;

DOI: <https://doi.org/10.1016/j.ijpharm.2017.05.062>

Khattabi, A. M.; Talib, W. H.; Alqdeimat, D. A.

**A targeted drug delivery system of anti-cancer agents based on folic acid-cyclodextrin-long polymer functionalized silica nanoparticles**

*Combination therapy of thymoquinone and melatonin, Carboxymethyl- $\beta$ -cyclodextrin (CMBCD)*

Journal of Drug Delivery Science and Technology, 2017, 41, 367 - 374;

DOI: <https://doi.org/10.1016/j.jddst.2017.07.025>



Salzano, G.; Wankar, J.; Ottani, S.; Villemagne, B.; Baulard, A. R.; Willand, N.; Brodin, P.; Manet, I.; Gref, R.

**Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs**

*Pulmonary route, Ethionamide, Booster, Tuberculosis, Combination therapy*

International Journal of Pharmaceutics, 2017, 531, 577 - 587;

DOI:<https://doi.org/10.1016/j.ijpharm.2017.05.030>

Varan, G.; Varan, C.; Erdogan, N.; Hincal, A. A.; Bilensoy, E.

**Amphiphilic cyclodextrin nanoparticles**

*Review, Protein and peptide drug delivery, Gene delivery*

International Journal of Pharmaceutics, 2017, 531, 457 - 469;

DOI:<https://doi.org/10.1016/j.ijpharm.2017.06.010>

Li, X.; Guo, T.; Lachmanski, L.; Manoli, F.; Menendez-Miranda, M.; Manet, M.; Guo, Z.; Wu, L.; Zhang, J.; Gref, R.

**Cyclodextrin-based metal-organic frameworks particles as efficient carriers for lansoprazole: Study of morphology and chemical composition of individual particles**

*Cubic morphologies with monodispersed size distributions, Homogeneity in terms of both drug loading and size*

International Journal of Pharmaceutics, 2017, 531, 424 - 432;

DOI:<https://doi.org/10.1016/j.ijpharm.2017.05.056>

Krzak, A.; Swiech, O.; Majdecki, M.; Bilewicz, R.

**Complexing daunorubicin with  $\beta$ -cyclodextrin derivative increases drug intercalation into DNA**

*Lipoic acid derivative of BCD, Aromatic linker*

Electrochimica Acta, 2017, 247, 139 - 148;

DOI:<https://doi.org/10.1016/j.electacta.2017.06.140>

Cyphert, E. L.; Zuckerman, S. T.; Korley, N. J.; Von Recum, H. A.

**Affinity interactions drive post-implantation drug filling, even in the presence of bacterial biofilm**

*In vitro filling/refilling model mimicking post-implantation tissue conditions, CD-based affinity polymer, Implanted or indwelling medical devices*

Acta Biomaterialia, 2017, 57, 95 - 102;

DOI:<https://doi.org/10.1016/j.actbio.2017.04.015>

Tricarico, D.; Maqoud, F.; Curci, A.; Camerino, G.; Zizzo, N.; Denora, N.; Cutrignelli, A.; Laquintana, V.; Lopalco, A.; la Forgia, F.; Fontana, S.; Franco, M.; Lopodota, A.

**Characterization of minoxidil/hydroxypropyl- $\beta$ -cyclodextrin inclusion complex in aqueous alginate gel useful for alopecia management: Efficacy evaluation in male rat**

*Activating in vitro the ATP-sensitive K<sup>+</sup>-channels (KATP), Enhanced hair growth, Topical long-term use*

European Journal of Pharmaceutics and Biopharmaceutics, 2018, 122, 146 - 157;

DOI:<https://doi.org/10.1016/j.ejpb.2017.10.015>

Semeraro, P.; Chimienti, G.; Altamura, E.; Fini, P.; Rizzi, V.; Cosma, P.

**Chlorophyll a in cyclodextrin supramolecular complexes as a natural photosensitizer for photodynamic therapy (PDT) applications**

*HPBCD, HPGCD, DIMEB, TRIMEB, Human colorectal adenocarcinoma HT-29 cell line, Phototoxicity*

Materials Science and Engineering C, 2018, 85, 47-56;



Perret, P.; Bacot, S.; Gèze, A.; (...); Riou, L.M.; Wouessidjewe, D.

**Biodistribution and preliminary toxicity studies of nanoparticles made of biotransesterified  $\beta$ -cyclodextrins and PEGylated phospholipids**

*Co-nanoprecipitation, Nanosuspension*

Materials Science and Engineering C, 2018, 85, 7-17;

Dos Santos, A. G.; Bayiha, J. C.; Dufour, G.; Cataldo, D.; Evrard, B.; Silva, L. C.; Deleu, M.; Mingeot-Leclercq, M.-P.

**Changes in membrane biophysical properties induced by the Budesonide/Hydroxypropyl- $\beta$ -cyclodextrin complex**

*Neutrophil-induced inflammation in a COPD mouse model, Cholesterol, Lipid packing*

Biochimica et Biophysica Acta (BBA) - Biomembranes, 2017, 1859, 1930 - 1940;

DOI:<https://doi.org/10.1016/j.bbamem.2017.06.010>

Liang, J.; Dong, X.; Wei, C.; Ma, G.; Liu, T.; Kong, D.; Lv, F.

**A visible and controllable porphyrin-poly(ethylene glycol)/ $\alpha$ -cyclodextrin hydrogel nanocomposites system for photo response**

*Multi-walled carbon nanotubes, Hydrogel disassembly, Fluorescence imaging tracking, Photothermal remote controlling*

Carbohydrate Polymers, 2017, 175, 440 - 449;

DOI:<https://doi.org/10.1016/j.carbpol.2017.08.023>

Münster, M.; Mohamed-Ahmed, A. H.A.; Immohr, L. I.; Schoch, C.; Schmidt, C.; Tuleu, C.; Breitzkreutz, J.

**Comparative *in vitro* and *in vivo* taste assessment of liquid praziquantel formulations**

*Taste masking agent, HPBCD, SBEB CD, Electronic tongue, Phase solubility study*

International Journal of Pharmaceutics, 2017, 529, 310 - 318;

DOI:<https://doi.org/10.1016/j.ijpharm.2017.06.084>

Alvarez-Lorenzo, C.; Garcia-Gonzalez, C. A.; Concheiro, A.

**Cyclodextrins as versatile building blocks for regenerative medicine**

*Affinity-driven regulated release of therapeutic molecules, Growth factors and gene vectors, Bioinks for 3D printing, Electrospun fibers, Cell differentiation, Syringeable implant*

Journal of Controlled Release, 2017, 268, 269 - 281;

DOI:<https://doi.org/10.1016/j.jconrel.2017.10.038>

Loftsson, T.; Stefansson, E.

**Cyclodextrins and topical drug delivery to the anterior and posterior segments of the eye**

*Solid drug/cyclodextrin complex microparticles, Dissolved drug/cyclodextrin complex nanoparticles, Studies in rabbits, Clinical evaluations in humans, Dorzolamide, Dexamethasone*

International Journal of Pharmaceutics, 2017, 531, 413 - 423;

DOI:<https://doi.org/10.1016/j.ijpharm.2017.04.010>

Maestrelli, F.; Mura, P.; Cirri, M.; Mennini, N.; Ghelardini, C.; Di Cesare Mannelli, L.

**Development and characterization of fast dissolving tablets of oxaprozin based on hybrid systems of the drug with cyclodextrins and nanoclays**

*Cofused system with RAMEB, Arginine and nanoclay, Pain relieving effect*

International Journal of Pharmaceutics, 2017, 531, 640 - 649;

DOI:<https://doi.org/10.1016/j.ijpharm.2017.05.033>





Shelat, R.; Chandra, S.; Khanna, A.

**Detailed toxicity evaluation of  $\beta$ -cyclodextrin coated iron oxide nanoparticles for biomedical applications**

*Acute toxicity analysis, Female Wistar rats, No significant toxic effect at the cellular level*

International Journal of Biological Macromolecules, 2017, - ;

DOI:<https://doi.org/10.1016/j.ijbiomac.2017.09.067>

Hao, W.; Liu, D.; Wang, Y.; Han, X.; Xu, S.; Liu, H.

**Dual-stimuli responsive nanoparticles (UCNP-CD@APP) assembled by host-guest interaction for drug delivery**

*Nanoparticles with pH- and photo-responsibility, BCD, Doxorubicin, Reversible isomerism*

Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2018, 537, 446 - 451;

DOI:<https://doi.org/10.1016/j.colsurfa.2017.10.038>

Loftsson, T.

**Drug solubilization by complexation**

*Tetracycline-metal ion complexes, Caffeine, Polyvinylpyrrolidone, Pharmacosomes*

International Journal of Pharmaceutics, 2017, 531, 276 - 280;

DOI:<https://doi.org/10.1016/j.ijpharm.2017.08.087>

Ijaz, M.; Prantl, M.; Lupo, N.; Laffleur, Hussain, A. M.; Matuszczak, B.; Bernkop-Schnürch, A.  
**Development of pre-activated  $\alpha$ -cyclodextrin as a mucoadhesive excipient for intravesical drug delivery**

*Cysteamine covalently attached to carbonyl groups of oxidized ACD, Thiolated ACD, L-Cysteine-2-mercaptosuccinic acid conjugate, Trimethoprim, Mucoadhesion, Bladder*

International Journal of Pharmaceutics, 2017, 534, 339 - 347;

DOI:<https://doi.org/10.1016/j.ijpharm.2017.10.054>

Li, M.; Li, Y.; Peng, K.; Wang, Y.; Gong, T.; Zhang, Z.; He, Q.; Sun, X.

**Conjugating CD with PEI, Instant massive protection against highly variant viruses, Intranasal vaccine delivery**

*Engineering intranasal mRNA vaccines to enhance lymph node trafficking and immune responses,*

Acta Biomaterialia, 2017, 64, 237 - 248;

DOI:<https://doi.org/10.1016/j.actbio.2017.10.019>

Gharib, R.; Fourmentin, S.; Charcosset, C.; Greige-Gerges, H.

**Effect of hydroxypropyl- $\beta$ -cyclodextrin on lipid membrane fluidity, stability and freeze-drying of liposomes**

*Dipalmitoyl phosphatidyl choline (DPPC) membranes, Cholesterol, Protection during freeze-drying*

Journal of Drug Delivery Science and Technology 2018, 44, 101-107

Malhotra, M.; Gooding, M.; Evans, J.C.; O'Driscoll, D.; Darcy, R.; O'Driscoll, C.M.

**Cyclodextrin-siRNA conjugates as versatile gene silencing agents**

*Amphiphilic polycationic cyclodextrin, Adamantyl-PEG-ligands*

European Journal of Pharmaceutical Sciences 2018, 114, 30-37



Hayashi, Y.; Higashi, T.; Motoyama, K.; (...), Ando, Y.; Arima, H.

***In vitro* and *in vivo* siRNA delivery to hepatocyte utilizing ternary complexation of lactosylated dendrimer/cyclodextrin conjugates, siRNA and low-molecular-weight sacran**

*Sacrans, Ternary complexes, Intravenous administration to mice, Hepatocyte-specific siRNA delivery system*

International Journal of Biological Macromolecules 2018, 107(PartA), 1113-1121

Heitor G. A.-F.; Pereira, E. W. M.; Rezende, M. M.; Menezes, P. P.; Araújo, A. A. S.; Barreto, R. S. S.; and Anita Martins, A. O. B. P. B.; Albuquerque, T. R.; Silva, B. A. F.; Alcantara, I. S.; Coutinho, H. D. M.; Menezes, I. R. A.; and Quintans-Junior, L. J.; Quintans, S. S. J.

**D-limonene exhibits superior antihyperalgesic effects in a  $\beta$ -cyclodextrin-complexed form in chronic musculoskeletal pain reducing Fos protein expression on spinal cord in mice**

*Fibromyalgia, Paw withdrawal threshold, Antinociceptive effect, Dorsal horn of the spinal cord*

Neuroscience, 2017, 358, 158 - 169;

DOI:<https://doi.org/10.1016/j.neuroscience.2017.06.037>

Binello, A.; Cravotto, G.; Boffa, L.; Stevanato, L.; Bellumori, M.; Innocenti, M.; Mulinacci, N.

**Efficient and selective green extraction of polyphenols from lemon balm**

*Melissa officinalis, Polyphenols, Rosmarinic acid, Ultrasound, Microwaves, Ball milling in the presence of BCD*

Comptes Rendus Chimie, 2017, 20, 921 - 926;

DOI:<https://doi.org/10.1016/j.crci.2017.06.003>

Blanford, W. J.; Pecoraro, M. P.; Heinrich, R.; Boving, T.B.

**Enhanced reductive de-chlorination of a solvent contaminated aquifer through addition and apparent fermentation of cyclodextrin**

*Residual HPBCD after soil flushing, Trichloroethylene, Trichloroethane, Dichloroethene, Anaerobic degradation, Electron donor*

Journal of Contaminant Hydrology, 2017, - ;

DOI:<https://doi.org/10.1016/j.jconhyd.2017.10.006>

Keskin, N. O. S.; Celebioglu, A.; Sarioglu, O. S.; Uyar, T.; Tekinay, T.

**Encapsulation of living bacteria in electrospun cyclodextrin ultrathin fibers for bioremediation of heavy metals and reactive dye from wastewater**

*Carrier matrix and feeding source for the encapsulated bacteria, Cell viability, Removal efficiency of nickel(II), chromium(VI)) and textile dye (Reactive Black 5, RB5)*

Colloids and Surfaces B: Biointerfaces, 2018, 161, 169 - 176;

DOI:<https://doi.org/10.1016/j.colsurfb.2017.10.047>

Wu, D.; Feng, Q.; Xu, T.; Wei, A.; Fong, H.

**Electrospun blend nanofiber membrane consisting of polyurethane, amidoxime polyacrylonitrile, and  $\beta$ -cyclodextrin as high-performance carrier/support for efficient and reusable immobilization of laccase**

*Chelation of Fe(III) ions, Catalytic activity, Thermal stability, Storage stability, Reusability*

Chemical Engineering Journal, 2018, 331, 517 - 526;

DOI:<https://doi.org/10.1016/j.cej.2017.08.129>



Villaverde, J.; Rubio-Bellido, M.; Lara-Moreno, A.; Merchan, F.; Morillo, E.

**Combined use of microbial consortia isolated from different agricultural soils and cyclodextrin as a bioremediation technique for herbicide contaminated soils**

*Diuron, HPBCD, Biodegradable organic enhancer of pollutant bioavailability, Combination with bioaugmentation*

Chemosphere, 2018, 193, 118 - 125;

DOI:<https://doi.org/10.1016/j.chemosphere.2017.10.172>

Annamalai, S.; Santhanam, M.; Selvaraj, S.; Sundaram, M.; Pandian, K.; Pazos, M.

**Green technology: Bio-stimulation by an electric field for textile reactive dye contaminated agricultural soil**

*In-situ formation of BCD from starch*

Science of The Total Environment, 2017, - ;

DOI:<https://doi.org/10.1016/j.scitotenv.2017.10.047>

Chen, P.-A.; Cheng, H.-C.; Wang, H. P.

**Activated carbon recycled from bitter-tea and palm shell wastes for capacitive desalination of salt water**

*Carbonization of Ag<sup>+</sup>-cyclodextrin complexes, Electrosorption efficiencies*

Journal of Cleaner Production, 2018, 174, 927 - 932;

DOI:<https://doi.org/10.1016/j.jclepro.2017.11.034>

Zhang, P.; Tugny, C.; Suárez, J. M.; Guitet, M.; Derat, E.; Vanthuyne, N.; Zhang, Y.; Bistri, O.; Mouriás-Mansuy, V.; Ménand, M.; Roland, S.; Fensterbank, L.; Sollogoub, M.

**Artificial chiral metallo-pockets including a single metal serving as structural probe and catalytic center**

*Capped metallo-cyclodextrins with silver, Gold or copper center, Regio- and stereoselectivities*

Chem, 2017, 3, 174 - 191;

DOI:<https://doi.org/10.1016/j.chempr.2017.05.009>

Dang, X.; Shan, Z.; Chen, H.

**Biodegradable films based on gelatin extracted from chrome leather scrap**

*Gelatin modified with BCD, Compatibility, Film-forming properties*

International Journal of Biological Macromolecules, 2017, - ;

DOI:<https://doi.org/10.1016/j.ijbiomac.2017.09.068>

An, X.; Ingole, P. G.; Choi, W. K.; Lee, H.-K.; Hong, S. U.; Jeon, J.-D.

**Development of thin film nanocomposite membranes incorporated with sulfated  $\beta$ -cyclodextrin for water vapor/N<sub>2</sub> mixture gas separation**

*Hydrophilic sulfonic acid groups, Decreased contact angle, Synergistic increase in both permeance and selectivity, Hollow fiber membrane, Water vapor separation*

Journal of Industrial and Engineering Chemistry, 2017, - ;

DOI:<https://doi.org/10.1016/j.jiec.2017.10.031>

Zhuo, S.; Wang, Y.; Kang, X.-F.

**Engineered protein nanopore for real-time monitoring single-molecule reaction between cadmium ion and glutathione**

*Intracellular cadmium detoxification,  $\alpha$ -Hemolysin protein nanopore equipped with a novel per-6-quaternary ammonium-BCD, Single-molecule nanopore technique*

Chinese Journal of Analytical Chemistry, 2017, 45, 1172 - 1178;

DOI:[https://doi.org/10.1016/S1872-2040\(17\)61032-6](https://doi.org/10.1016/S1872-2040(17)61032-6)



Immohr, L. I.; Pein-Hackelbusch, M.

**Development of stereoselective e-tongue sensors considering the sensor performance using specific quality attributes—A bottom up approach**

*BCD, Hydroxypropyl-BCD, Cyclodextrin oligomer, Sulfobutylethylether-BCD, Triacetyl-BCD, Heptakis(2,6-di-O-methyl)-BCD, Chiral recognition, Glutamic acid, Asparagine, Praziquantel*  
Sensors and Actuators B: Chemical, 2017, 253, 868 - 878;  
DOI: <https://doi.org/10.1016/j.snb.2017.06.157>

Kun, Q.; Lin, Y.; Peng, H.; Cheng, L.; Cui, H. F.; Hong, N.; Xiong, J.; Fan, H.

**A "signal-on" switch electrochemiluminescence biosensor for the detection of tumor cells**

*Circulating tumor cells, Composite of Ru(bpy)<sub>3</sub><sup>2+</sup>/BCD-Au nanoparticles, Ferrocene-labeled aptamers*  
Journal of Electroanalytical Chemistry, 2017, - ;  
DOI: <https://doi.org/10.1016/j.jelechem.2017.11.031>

Fayad, S. J.; Minatti, E.; Soldi, V.; Fort, S.; Labbac, P.; Borsali, R.

**A versatile nanoarray electrode produced from block copolymer thin films for specific detection of proteins**

*Poly(styrene-*b*-methacrylate), Nanopores, BCD, Biotin unit, Detection of streptavidin*  
Polymer, 2017, 123, 128 - 136;  
DOI: <https://doi.org/10.1016/j.polymer.2017.07.015>

Li, X.; Du, Y.; Feng, Z.; Sun, X.; Huang, Z.

**A novel enantioseparation approach based on liposome electrokinetic capillary chromatography**

*SBEB CD, phosphatidylcholine, Cholesterol, Naproxen, Warfarin, Ketoprofen, Amlodipine*  
Journal of Pharmaceutical and Biomedical Analysis, 2017, 145, 186 - 194;  
DOI: <https://doi.org/10.1016/j.jpba.2017.06.008>

Yan, X.; Li, J.; Yang, R.; Li, Y.; Zhang, X.; Chen, J.

**A new photoelectrochemical aptasensor for prion assay based on cyclodextrin and Rhodamine B**

*Au-TiO<sub>2</sub> composite, Rhodamine B labeled prion-aptamer*  
Sensors and Actuators B: Chemical, 2018, 255, Part 2, 2187 - 2193;  
DOI: <https://doi.org/10.1016/j.snb.2017.09.030>



Edited and produced by: CYCLOLAB  
Homepage: [www.cyclolab.hu](http://www.cyclolab.hu)  
H-1525 P.O. 435, Budapest,  
Hungary  
Tel.: (+361)347-6060  
Fax.: (+361)347-6068  
e-mail: [cyclolab@cyclolab.hu](mailto:cyclolab@cyclolab.hu)

